The FDA has accepted the BLA for lecanemab-irmb SC for weekly maintenance dosing in the treatment of early Alzheimer disease.

Ozempic, Rybelsus and Wegovy top the list of the newest drugs selected for Medicare Part price negotiation, part of the ...

GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...

Biogen Inc. (BIIB), headquartered in Cambridge, Massachusetts, specializes in discovering, developing, manufacturing, and ...

The US Food and Drug Administration (FDA) has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs ...

As I ran from interview to interview across San Francisco, I was consistently warmed by the stories I was told by biotech and ...

More than half (53%) of patients reached remission after one year of Omvoh treatment and 46% experienced healing of the ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

The FDA established its accelerated approval program in 1992 to allow drugs to reach the market quickly for life-threatening ...